Xenetic Biosciences, Inc. (XBIO )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol XBIO
- Company Xenetic Biosciences, Inc.
- Price $3.12
- Changes Percentage -7.69
- Change -0.26
- Day Low $2.82
- Day High $3.26
- Year High $13.93
- Year Low $1.9
- Market Cap $4,070,975
- Price Avg 50 EMA (D) $2.3
- Price Avg 200 EMA (D) $3
- Exchange NASDAQ
- Volume 105,532
- Average Volume 26,598
- Open $3.24
- Previous Close $3.38
- EPS -2.04
- PE -1.29
- Earnings Announcement 2026-03-25 12:00:00
- Shares Outstanding $1,542,036
Company brief: XENETIC BIOSCIENCES, INC. (XBIO )
- Healthcare
- Biotechnology
- Mr. James F. Parslow
- https://www.xeneticbio.com
- US
- N/A
- 06-30-2016
- US9840156023
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
XBIO Corporation News
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results
accessnewswire.com -- Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat cancers Strategic focus on investigator-initiated exploratory studies and institut...